$1.14/ day, billed weekly
Cancel anytime

(Ads Free, Unlimited access)

NO CREDIT CARD REQUIRED

Climb Bio Inc (CLYM)CLYM

Climb Bio Inc

$3.51

Delayed price

PASS

BUY Advisory
Profitable SELL
Loss-Inducing SELL

Profit
Loss
PASS (Skip invest)*

Time period over

ALL
YEAR
MONTH
WEEK

Time period over

Upturn Advisory Summary

11/04/2024: CLYM (1-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance

Type: Stock	Upturn Star Rating	Today’s Advisory: PASS
Historic Profit: -56.74%	Upturn Advisory Performance 1	Avg. Invested days: 22
Profits based on simulation	Stock Returns Performance 1	Last Close 11/04/2024

Type: Stock	Today’s Advisory: PASS
Historic Profit: -56.74%	Avg. Invested days: 22
Upturn Star Rating	Stock Returns Performance 1
Profits based on simulation Last Close 11/04/2024	Upturn Advisory Performance 1

Key Highlights

Company Size ETF	Market Capitalization 0 USD
Price to earnings Ratio -	1Y Target Price -
Dividends yield (FY) -	Basic EPS (TTM) -
Volume (30-day avg) 659697	Beta -
52 Weeks Range 2.35 - 11.55	Updated Date 10/11/2024

Company Size ETF	Market Capitalization 0 USD	Price to earnings Ratio -	1Y Target Price -
Dividends yield (FY) -	Basic EPS (TTM) -	Volume (30-day avg) 659697	Beta -
52 Weeks Range 2.35 - 11.55	Updated Date 10/11/2024

Earnings Date

Report Date 2024-11-13	When -
Estimate -	Actual -0.1327

Report Date 2024-11-13

When -

Estimate -

Actual -0.1327

Profitability

Profit Margin -

Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -

Return on Equity (TTM) -

Valuation

Trailing PE -	Forward PE -
Enterprise Value -	Price to Sales(TTM) -
Enterprise Value to Revenue -	Enterprise Value to EBITDA -
Shares Outstanding -	Shares Floating -
Percent Insiders -	Percent Institutions -

Trailing PE -	Forward PE -	Enterprise Value -	Price to Sales(TTM) -
Enterprise Value to Revenue -	Enterprise Value to EBITDA -	Shares Outstanding -	Shares Floating -
Percent Insiders -	Percent Institutions -

Analyst Ratings

Rating -	Target Price -	Buy -
Strong Buy -	Hold -	Sell -
Strong Sell -

Rating -	Target Price -	Buy -	Strong Buy -
Hold -	Sell -	Strong Sell -

About Climb Bio Inc

Exchange	NASDAQ	Headquaters	Wilmington, DE, United States
IPO Launch date	2021-08-10	CEO, President & Director	Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc
Sector	Healthcare	Website	https://eliemtx.com
Industry	Biotechnology	Full time employees	9
Headquaters	Wilmington, DE, United States
CEO, President & Director	Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc
Website	https://eliemtx.com
Website	https://eliemtx.com
Full time employees	9

Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.

https://www.upturn.io

Disclosure Privacy Policy Terms of Use Sitemap Contact Us

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.